This article is more than 5 years old. Information may no longer be current.
Shipments of thyrotropin alfa expected to resume this week
Click Here to Manage Email Alerts
Genzyme, the manufacturer of thyrotropin alfa for injection, has notified US health care providers that it will be able to release shipments during the week of June 20.
The company qualified the notice as a "best estimate of anticipated resumption of US Thyrogen supply" and stated that the inventory is extremely limited so that even minor changes to their current manufacturing plan can impact the timing of availability, according to a press release by the American Thyroid Association.
Thyrotropin alfa (Thyrogen) is indicated for use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy and as an adjunctive diagnostic tool for serum thyroglobulin testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer, according to Genzyme.
Genzyme notified health care providers of this anticipating timing of shipment resumption so that individual patient treatments may be scheduled appropriately. Thyrotropin alfa has been linked to major shortages in the past year, with reports of limited inventory and manufacturing irregularities at Genzyme’s production facilities.
 |
Follow EndocrineToday.com on Twitter. |